A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced
A phase 1/2 trial of PM8002 in non-small-cell lung cancer and small-cell lung cancer, run by BioNTech SE, now recruiting.
Overview
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 1/2 interventional study registered as NCT07111520 by BioNTech SE, with 880 participants planned, started 2025-09-22 and due to reach its primary completion in 2028-11. Interventions recorded: BNT326, Pumitamig. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Shares PM8002, BioNTech, Small-cell lung cancer.
- TrialSafety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
Shares PM8002, BioNTech, Small-cell lung cancer.
- TrialPM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
- TrialPM8002 in the Treatment of Patients With Advanced Solid Tumors
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- TrialA First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors